Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19

Aamodt, Anne Hege; Høgestøl, Einar August; Popperud, Trine Haug; Holter, Jan Cato; Dyrhol‐Riise, Anne Ma; Tonby, Kristian; Stiksrud, Birgitte; Quist‐Paulsen, Else; Berge, Tone; Barratt‐Due, Andreas; Aukrust, Pål; Heggelund, Lars; Blennow, Kaj; Zetterberg, Henrik; Harbo, Hanne F.

doi:10.1101/2020.09.07.20189415

Cited by 18 publications

(20 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, GFAP, UCH-L1, and NfL positively correlated with Intensive Care Delirium Screening Checklist score and were increased in patients with delirium in the COVID-19 group but not in the ICU controls [ 24 ]. In another study, NfL and GFP blood levels measured at hospitalization were found to be more elevated in patients with fatal outcome [ 25 ]. A small study investigating a large number of biomarkers, has found elevated total tau levels in blood extracellular vesicles in COVID-19 patients as compared to historical controls [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

Blood neurofilament light chain and total tau levels at admission predict death in COVID-19 patients

et al. 2021

View full text Add to dashboard Cite

Background and aims Patients infected with SARS-CoV-2 range from asymptomatic, to mild, moderate or severe disease evolution including fatal outcome. Thus, early predictors of clinical outcome are highly needed. We investigated markers of neural tissue damage as a possible early sign of multisystem involvement to assess their clinical prognostic value on survival or transfer to intensive care unit (ICU). Methods We collected blood from 104 patients infected with SARS-CoV-2 the day of admission to the emergency room and measured blood neurofilament light chair (NfL), glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), and total tau protein levels. Results We found that NfL, GFAP, and tau were significantly increased in patients with fatal outcome, while NfL and UCH-L1 in those needing ICU transfer. ROC and Kaplan–Meier curves indicated that total tau levels at admission accurately predict mortality. Conclusions Blood neural markers may provide additional prognostic value to conventional biomarkers used to predict COVID-19 outcome. Supplementary Information The online version contains supplementary material available at 10.1007/s00415-021-10595-6.

show abstract

Section: Discussionmentioning

confidence: 99%

Blood neurofilament light chain and total tau levels at admission predict death in COVID-19 patients

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In fact, recent studies revealed elevated NfL levels during COVID-19, irrespective of the clinical course ( 32 , 33 ). Moreover, increased NfL concentrations at the time of admission of COVID-19 patients were linked to a higher mortality risk ( 34 ). This is of interest as SARS-CoV-2 primarily affects the respiratory system, and a direct impact on neurons has not ultimately been clarified ( 35 – 37 ).…”

Section: Discussionmentioning

confidence: 99%

Tetravalent Influenza Vaccine Is Not Associated With Neuroaxonal Damage in Multiple Sclerosis Patients

et al. 2021

View full text Add to dashboard Cite

BackgroundEfficacy of vaccines and disease activity linked to immunization are major concerns among people with multiple sclerosis (pwMS).ObjectiveTo assess antibody responses to seasonal influenza antigens and vaccine-associated neuroaxonal damage utilizing serum neurofilament light chain (sNfL) in pwMS receiving dimethyl fumarate (DMF).MethodsIn this prospective study, the 2020/2021 seasonal tetravalent influenza vaccine was administered to 20 pwMS treated with DMF and 15 healthy controls (HCs). The primary endpoints were responder rate of strain-specific antibody production (seroconversion or significant (4-fold) increase in influenza-antibody titers for ≥2/4 strains) at 30 days post-vaccination and changes in sNfL levels.ResultsAll patients treated with DMF fulfilled the responder criteria for immunization compared with 53% of the controls. However, higher proportions of HCs already had influenza-antibody titers ≥1:40 at baseline (53% vs. 41%, p = 0.174). sNfL levels were comparable among both groups at baseline and did not increase 34 days after vaccination. In addition, no clinical or radiological disease reactivation was found.ConclusionDMF-treated patients mount an adequate humoral immune response to influenza vaccines. Within the limits of the small cohort investigated, our data suggest that influenza immunization is not associated with clinical or subclinical disease reactivation.

show abstract

“…Serum levels of neurofilament light chain (NfL), a biomarker of axonal damage, may be increased during COVID-19 acute phase (Aamodt et al 2021 ), even in the absence of overt neurological signs, suggesting a possible SARS-CoV-2 neuronal trophism (Mariotto et al 2020 ). The possible association between chronic fatigue and serum NfL levels has not been determined in this condition, yet.…”

Section: Introductionmentioning

confidence: 99%

Chronic fatigue syndrome: an emerging sequela in COVID-19 survivors?

et al. 2021

View full text Add to dashboard Cite

SARS-CoV-2 survivors may report persistent symptoms that resemble myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). We explored (a) ME/CFS-like symptom prevalence and (b) whether axonal, inflammatory, and/or lung changes may contribute to ME/CFS-like symptoms in SARS-CoV-2 survivors through clinical, neuropsychiatric, neuropsychological, lung function assessment, and serum neurofilament light chain, an axonal damage biomarker. ME/CFS-like features were found in 27% of our sample. ME/CFS-like group showed worse sleep quality, fatigue, pain, depressive symptoms, subjective cognitive complaints, Borg baseline dyspnea of the 6-min walking test vs. those without ME/CFS-like symptoms. These preliminary findings raise concern on a possible future ME/CFS-like pandemic in SARS-CoV-2 survivors.

show abstract

Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19

Cited by 18 publications

References 30 publications

Blood neurofilament light chain and total tau levels at admission predict death in COVID-19 patients

Blood neurofilament light chain and total tau levels at admission predict death in COVID-19 patients

Tetravalent Influenza Vaccine Is Not Associated With Neuroaxonal Damage in Multiple Sclerosis Patients

Chronic fatigue syndrome: an emerging sequela in COVID-19 survivors?

Contact Info

Product

Resources

About